AGTX Agentix Corp.

CIK 0001603345 4 ready 8-Ks latest December 21, 2021, 6:59 PM ET RSS · JSON

Ready 8-Ks 4

Latest filing June 14, 2022, 7:59 PM ET

Top materiality 0.65

Event mix m_and_a ×2 · leadership ×1 · other_material ×1

Sentiment 1 pos · 0 neg · 3 neu

Executive change recent →

Recent 8-K filings for AGTX

Highest-materiality recent filing

Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates

December 21, 2021, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.
Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.

December 21, 2021, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates

License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.
July 16, 2021, 7:59 PM ET M&A materiality 0.60 neutral item 2.01 item 9.01

Agentix Corp. completes merger with Applied Biopharma LLC; interests converted to common stock

Merger completed July 14, 2021: AB Merger LLC merged into Applied Biopharma, with Applied Biopharma surviving.

Appointed

member of the board of directors

AGTX · Agentix Corp.

On June 11, 2022, the board of directors of Agentix Corp. (the “Company”) appointed Salman Hoda as a member of the board of directors of the Company.

Max materiality 0.65 · Median 0.45 · Most common event m_and_a

1 positive 0 negative 3 neutral